Background: The care transition is the time when more medication errors occur. The aim of this study is to analyze the usefulness of a pharmacotherapeutic report model at hospital discharge to prevent medication errors and to simplify pharmacotherapy during a patient's transition from the hospital to primary care. Methods: Prospective study including patients diagnosed with chronic obstructive pulmonary disease who were admitted to a short-stay unit or an emergency room. Relevant variables were extracted from the patients' clinical history and SPSS software was used to carry out the statistical analysis. Direct costs were also calculated. Results: 79.3% of patients were polymedicated, 15.5% of patients were identified as nonadherent to the treatment, 12.1% were users of alternative therapies, and 10.3% had been prescribed drugs that could be monitored. In 32.8% of the reports, reference was made to the primary care pharmacists with a view to resolve any pharmacotherapeutic discrepancies. A total of 132 discrepancies were identified, the majority being related to medicinal requirements (necessary/unnecessary medication). The major cause of drug-related problems (DRPs) were prescription errors. The drugs that were mainly involved in the onset of DRPs belonged to the R group, and the degree of simplification of the pharmacotherapy was 7.6%. The total cost avoided with the reconciliation was 200€/patient. Conclusion: A continuity program was implemented based on the drafting of a pharmacotherapeutic report, which allowed for detecting discrepancies and updating the patients' pharmacotherapeutic history, resulting in financial savings after its implementation.
Introduction
The current health care model is particularly focused on patient care and tends to overlook compartmentalized health care. To this end, many autonomous communities are developing health care management areas integrating primary care (PC) and specialized care (SC). 1 The incorporation of new technologies is fundamental for an adequate continuity of care (CC). 2 However, their existence does not necessarily entail that a patient's medical history is accurate, with one of the most critical moments for patients being the process of care transition. The flow of patients between different care levels is a key process associated with several risks, including those concerning drug-related adverse events, the need for longer hospital stays, visits to the emergency room, or readmissions. 3 Pluripathological patients play a unique role in this health care transition process, 4 as they are continuously transferred from one level of care to another and are frequently subject to changes in their treatment regimens.
At present, chronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic diseases reported worldwide, affecting 4% to 10% of the population, and, therefore, is a key pathology in the chronicity action plans that are being developed by different national and international health care systems. 5, 6 Discrepancies taking place after hospital discharge can lead to the onset of adverse events, an increased length of hospitalization, or even to hospital readmissions. 3, 7, 8 Several reconciliation studies have revealed that many of these adverse events result from a poor management of the health care transition process. 9 A meta-analysis carried out with more than 20,000 patients found a relative risk reduction of 67%, 28%, and 19% in the group of reconciled patients as compared to the group of nonreconciled patients with respect to drug-related adverse events, hospital readmissions, and visits to the emergency room, respectively. 8 According to the US government, the annual cost of hospital readmissions exceeds $17 trillion. 10 Detecting discrepancies or drug-related problems (DRPs) at the time of the health care transition by means of the drafting of a pharmacotherapeutic report at hospital discharge in a group of patients with a chronic pathology will enable the creation of a continuity of care program where strategic multidisciplinary collaboration will be fundamental to improve pharmacotherapy in patients.
The main objective of this study was to analyse the usefulness of a pharmacotherapeutic report model at hospital discharge, integrated into the patients' electronic history, to prevent medication errors and to simplify pharmacotherapy during the transition of a patient with COPD from the hospital to a PC.
The secondary objectives were 1. to identify the types and causes of the discrepancies detected; 2. to estimate the costs avoided by simplifying the pharmacotherapy; 3. to detect possible risk factors related to a greater number of discrepancies in patients' medications; and 4. to determine the number of follow-up recommendations specific to hospital discharge given to the PC in the CC pharmacotherapeutic report.
Methods
A 5-month prospective study was carried out in an integrated management organizational structure providing health care services to over 600,000 inhabitants and consisting of 1275 hospital beds and 53 PC centers. The study's target population met the following inclusion criteria: patients with COPD, hospitalized in a short stay unit or in emergency room (ER) observation beds. Patients who refused to participate and those for whom the necessary data were not available were excluded from the study.
Study Variables
The general variables were as follows: demographics (sex), comorbidities (Charlson index, COPD classification); caregiver and home treatment; number of total medications, medications subject to monitoring, medications subject to safety alerts, and adherence to treatment (Morisky-Green test).
The outcome variables were as follows: percentage of discrepancies detected in the drug reconciliation at discharge; percentage of discrepancies related to the need, safety, and efficacy of treatment; percentage of simplification of the pharmacotherapeutic regimen at discharge and associated savings; and percentage of reports with follow-up recommendations for the PC.
In order to estimate the costs avoided by the health care system, the difference between the cost of the pharmacotherapeutic treatment at hospital discharge and admission was calculated based on the e-prescription system of the patients' electronic history, after it was updated by the multidisciplinary team on the patient's discharge from the hospital.
Statistical Analysis
The Kolmogorov-Smirnov test was used to evaluate the normality of the quantitative variables. Those that followed a normal distribution were expressed as means and standard deviations and were analyzed with parametric tests. Those that did not follow a normal distribution were expressed as medians and interquartile ranges and were analysed with nonparametric tests.
Qualitative variables were expressed in terms of frequencies and percentages. As for dichotomous variables, their probability was calculated using a chi-square test, or Fisher exact test. Analysis of variance or Kruskal-Wallis test was used if 2 or more categories had to be analyzed.
A P value <.05 was considered to be statistically significant.
Ethical Aspects
All staff who participated in the processing of personal data were bound to professional secrecy and confidentiality with respect to said information. All data collected for the study were treated according to the safety measures established in compliance with Organic Law 15/1999 on Personal Data Protection. The data were registered in an encrypted and confidential data collection logbook, kept within the integrated management organizational structure. This study was carried out following standard clinical practice guidelines, without any additional intervention. The pharmacists working at PC and SC are professionals of the Galician Health care Service and their daily work is based on such patients. The only information collected was that associated with DRPs, the pharmacotherapeutic group to which the drugs belonged, their classification, and the costs avoided. The main objective of this study was to detect discrepancies and to implement a better coordinated working procedure, not to obtain patient data. The rationale behind not obtaining a written informed consent from patients is also explained by the above.
Results
Between July 1 and October 30, 2015, 58 patients (82.7% men) with COPD (8.6% acute type with an associated emphysema, 19% acute type and associated with chronic bronchitis, and 10.3% mixed type) were enrolled in the study. Of these, 74.1% were admitted to a short stay unit and 25.9% were admitted to an ER.
The mean Charlson score was 7.2, and 79.3% of patients were considered to be polymedicated (they took more than 6 medications at home). The mean number of drugs prescribed before their admission was 10.8 drugs/patient. 6.9% of patients were taking alternative therapies, and over 80% of them were defined as "non-users" of such therapies. Furthermore, 10.3% of patients had been prescribed a drug that could be monitored (digoxin and theophylline), and almost 20% had been prescribed a drug linked to a safety alert issued by the Spanish Agency for Medicines and Sanitary Products (AGEMED).
Additionally, 15.5% of patients were identified as nonadherents based on the results of the Morisky-Green test.
In 60.3% of cases, the patient was the one in charge of his/ her home treatment, whereas in the remaining 39.7% it was a relative (the family member was present in 82.6% of the interviews) who was in charge of administering such treatment.
As a CC project in which these pharmacotherapeutic reports at hospital discharge were available for PC professionals, the PC centers to which the patients belonged were also recorded (data not shown). Furthermore, the PC centers were involved in the drafting of the CC reports, given that an intervention on their part was included for certain patients (32.8% of the reports referred to the PC professionals to resolve discrepancies in the patients' pharmacotherapy).
A total of 627 home treatments were reconciled at discharge, with at least 1 discrepancy being detected in 86.2% of patients. We identified a total of 132 discrepancies, with an average of 2.3 discrepancies/patient.
The causes of the discrepancies identified are set out in Figure  1 , considering 46% of them as being related to need, 27% to effectiveness and 27% to safety. Among those associated with need, the most frequent ones were prescription errors (including the fact that the drug was not indicated for such treatment or that the dose-schedule-duration was unintentionally incorrect). Regarding effectiveness, the major cause of discrepancy was noncompliance. As for drug safety, the most frequent cause was the likelihood of onset of adverse effects. Moreover, it was estimated that 5.2% of patients followed home treatments with significant interactions. The drugs that lead most often to discrepancies belonged to the R (25%) and C groups (24%) (Figure 2) .
The annual cost of the patients' home drug treatments at admission was €4687 (standard deviation [SD] ¼ 13,701). After the reconciliation and correction of the discrepancies, the mean cost at discharge was €4484 (SD ¼ 13,764 ). This data update at discharge of all scripts of the electronic prescription system of the e-prescription program resulted in savings of €200 per patient.
The degree of simplification of the pharmacotherapy was 7.6%, and the percentage of unnecessary medications taken by chronic polymedicated patients was 8.4%. A greater number of discrepancies was identified in males compared to females (P ¼ .024). However, no significant relationship was observed when the person in charge of the treatment was the patient himself/herself, neither with regard to the nonadherence nor with respect to age, comorbidity, or polypharmacy.
Discussion
This study complies with the main quality recommendations of organizations such as the Joint Commission and other international organizations related to patient safety, such as the Institute for Health care Improvement and the WHO. These institutions highlight the need to establish CC strategies and drug reconciliation procedures to prevent medication errors and ensure the safety of chronic treatments.
11
The high prevalence of COPD, as well as its burden for health care services, makes it an ideal pathology for the conduct of a study concerning coordination and medication reconciliation. Moreover, in many cases, a patient is diagnosed with COPD even when the tests indicated for its correct diagnosis have not been carried out or the type of COPD has not been recorded properly, as reflected by the results of this study. The type of COPD was not registered in most patient cases included in this study, although the medical history did describe the severity of the disease.
The number of medications taken by these patients is consistent with the concept of aging and the definition of chronic multipathologic patients. 12 Not all studies indicate the percentage of polymedicated patients, and different definitions of the term tend to be used in those that do. 13 The use of alternative therapies may lead to interactions with patients' pharmacotherapy, and these therapies are not reflected in usual drug prescriptions. Given the above, this variable was very useful in CC pharmacotherapeutic reports, as it incorporates this information into the patients' electronic history. In our study, the use of alternative therapies turned out to be lower than expected, given that in Spain the approximate prevalence ranges from 25% to 45%.
14 A possible explanation for this lower incidence is the profile of the patients that were enrolled in our study (mainly nononcological and elderly patients). The average number of medications taken chronically by the patients was similar to that reported in some studies, 15 but lower than that reported in others. 16 The Charlson index 17 is an index designed to classify patients into different risk groups. Most of the studies analysed did not describe this comorbidity index, and the percentage of patients with a high morbidity in our study (34.5%) was greater than that of other studies (3.2%). 18 Recently, the International Society for Pharmacoeconomics and the Research of Healthcare Results defined the term adherence as the degree to which a patient complies with the prescribed dose, dosage schedule, and treatment deadline. 19 There are different methods available to measure patient adherence to treatment, including the Morisky-Green questionnaire used in this study as an indirect and subjective method, 20 with which we identified a low percentage of nonadherent patients considering that approximately 1 of every 2 chronic patients did not take their medication properly. 21 Some factors that can predict poor treatment adherence in elderly patients include an increased number of prescribing physicians, polymedication, the complexity of the dosing regimen, depression and cognitive impairment. 22 New medications have changed the natural history of several diseases, often leading to their chronification. However, despite all the advantages that they offer, they can still result in adverse drug reactions. Pharmacovigilance is a key element to prevent these effects, and this study seeks to alert health professionals to the adverse reactions resulting from recently commercialized drugs by including a pharmacovigilance section in CC reports. In our study, the percentage of patients who had been prescribed a drug associated with a safety alert issued by the AEMPS (Spanish Agency of Medicinal Products and Medical Devices) was astonishing. This opens a great field of action to the pharmacist in charge of the reconciliation process.
In this study, at least 1 discrepancy was identified in over 80% of patients. This is a high figure, yet similar to those reported in other studies (75.4%-95.9%). 23, 24 The mean number of discrepancies detected per patient was also comparable to that of other studies, ranging from 2.4 to 2.9.
23-26
The main causes of such discrepancies were related to medicinal requirements (necessary or unnecessary medication, such as prescription errors). Other observational studies coincide with ours, reporting a high percentage of disaggregation discrepancies at discharge associated with medicinal requirements (necessary / unnecessary). In another reconciliation study at discharge carried out with 340 patients, a total of 992 discrepancies were detected, 23 with the majority being linked to prescription errors and excessive treatment duration. In said study, the percentage of interactions (safety discrepancy) detected was 10%, which is a somewhat higher figure than that obtained in our study. As for drug interactions, the higher value reported in the above-mentioned study may owe to the fact that in our study we only recorded clearly significant interactions and that these were few compared to those described by these and other authors. 15 Moreover, in another study with a similar sample population size (374 patients), 24 the treatment dose or an insufficient treatment duration were the most common discrepancies identified, also at a percentage equal to that calculated in our study.
In our study, the higher percentage of R group drugs involved in the onset of DRPs clearly owes to the fact that our project involved patients with COPD and that many of the discrepancies were related to inhaled therapies. Our patient profile also explains the fact that theophylline was included in the list of active ingredients detected in patients susceptible to monitoring, since these patients tend to be candidates for treatment with this drug. We did not identify any study analyzing medications susceptible of being monitored during the health care transition. Group C ranked second in our study owing to the fact that it is one of the most frequently prescribed drug groups, 26 also holding leading positions in other reconciliation studies. 27, 28 Our statistical analysis did not provide any sort of explanation for the greater number of discrepancies found in men compared to women. Some studies have shown that patients with a greater number of comorbidities are more likely to have drug discrepancies, 24 although this could not be replicated in our study. We did not find any statistically significant relation between the existence of discrepancies in patients and their age, the number of medications taken by each patient, or the days of hospitalization. Ahmad et al 23 found no differences with respect to the patients' sex, age, or the number of medications taken by each patient. One study revealed a greater number of discrepancies in patients younger than 80 years who had stayed at the hospital for more than 3 days, although these results were not statistically significant. Other studies have also found similar differences among these patient groups. 24 This brings to light the need to try new approaches in this field of research. We believe that a larger sample size and a longer time horizon would yield the results that can be inferred from those described in our study.
The direct savings estimated in our study are very similar to those reported by Surbhi et al, 24 who calculated a cost reduction of $293.30 for each DRP identified. Other studies take into account the costs of the program in itself, and calculate a saving of $2 for every $1 invested 29 or $12 for every $1 invested in the pharmacist's time. 25 In our study, the cost of a patient's home medication at admission was higher than after carrying out the reconciliation at discharge and after correcting all discrepancies found. Although the cost was lower, we consider that the savings could have been even greater, given that new drugs are always incorporated into a patient's treatment regimen at discharge. In our study, we did not consider indirect costs associated with discrepancies related to the health care transition process; hence, we believe that future research should contemplate this variable in order to obtain more precise results to evaluate the efficiency of these strategies.
Our continuity of care program was based on the drafting of a pharmacotherapeutic report integrated into the common electronic history of primary health care and specialized health care. Other colleagues work with similar programs-not including this report-that are also aimed at achieving drug reconciliation and adherence. 18 Other research work carried out by multidisciplinary teams also seeking to ensure continuity of care use different tools after patient discharge (often telephone calls or home visits) to ensure a smooth transition. In our case, we considered that some of the interventions could be referred to PC professionals, thus achieving a transversal care model. Drug reconciliation has been identified as a crucial intervention to address and reduce the burden of drug discrepancies and medication errors during health care transitions. 29 CC programs help reduce such discrepancies at hospital discharge and, therefore, prevent potential DRPs.
Conclusion
In conclusion, we identified and solved discrepancies detected during the health care transition process thanks to the development of a CC pharmacotherapeutic report model at hospital discharge, integrated into the electronic history and accessible at both levels of care. Furthermore, the update of the patients' active medication in the electronic medical history enabled an adequate and safe health care transition and resulted in significant savings after implementing the program.
